DelveInsight “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Non-Small Cell Lung Cancer Market Share @ Non-Small Cell Lung Cancer Market Outlook

Key Takeaways from the Non-Small Cell Lung Cancer Market Report

• In April 2025, Merck Sharp & Dohme LLC announced a Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC).
• In April 2025, Allist Pharmaceuticals Inc. conducted a phase 3 study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.
• In April 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) inhibitor (budigalimab) to adult participants to treat NSCLC.
• About 10–15% of all lung cancers are SCLC, and about 80–85% are Non-Small Cell Lung Cancer.
• In the US, in 2024, there were approximately 204,800 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
• The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, approximately 59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 6% of all lung cancers.
• Among the age-specific contribution, age =65 years are affected more by NSCLC than age
• In 2024, the total incident cases of NTRK1/2/3 gene fusion NSCLC in the US was around 450.
• In biomarker specific specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR. On the other hand, NTRK accounted for least number of cases whereas, BRAF accounted for approximately 5% cases.
• The two main subtypes of KRAS NSCLC are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~4,900 comprised of KRAS G12C, and ~13,300 comprised of KRAS non-G12C in 2024.
• The increase in Non-Small Cell Lung Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Non-Small Cell Lung Cancer Market is anticipated to witness growth at a considerable CAGR.
• The leading Non-Small Cell Lung Cancer Companies such as Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.
• Promising Non-Small Cell Lung Cancer Pipeline Therapies such as Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.

Stay ahead in the Non-Small Cell Lung Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Non-Small Cell Lung Cancer Market Outlook

Non-Small Cell Lung Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of Non-Small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total incident cases of NSCLC
• Gender-specific cases of NSCLC
• Age-specific cases of NSCLC
• Total incident cases of NSCLC by histology
• Total cases of NSCLC by stages
• Total incident cases of NSCLC by genetic mutation/biomarkers
• Line wise Treated Cases of Metastatic NSCLC

Download the report to understand which factors are driving Non-Small Cell Lung Cancer Epidemiology trends @ Non-Small Cell Lung Cancer Prevalence

Non-Small Cell Lung Cancer Marketed Drugs

• KEYTRUDA (pembrolizumab): Merck

KEYTRUDA is a PD-1-blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-L1. KEYTRUDA was first approved in October 2015 by the US FDA as a monotherapy for metastatic NSCLC. Later, the labels were expanded in 2016, 2017, 2018, and in 2023. In October 2023, the FDA approved KEYTRUDA platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent KEYTRUDA as post-surgical adjuvant treatment for resectable (tumors =4 cm or node positive) NSCLC. The drug has also received approvals in EU4 and the UK (August 2016) and Japan (December 2016), where the labels were expanded as well. Recently in September 2024, Merck announced that the MHLW has approved new indications for KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment. Earlier in March 2024, Merck announced that the EC has approved KEYTRUDA in combination with platinum-containing chemotherapy as neoadjuvant treatment

• TECENTRIQ (atezolizumab): Genentech/Roche

TECENTRIQ is a PD-L1-blocking antibody. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular mass of 145 kDa. According to Roche’s recent product development portfolio published in October 2024, the company anticipates submitting a filing for TECENTRIQ in the periadjuvant treatment of NSCLC in 2025.

Non-Small Cell Lung Cancer Emerging Drugs

• Telisotuzumab vedotin: AbbVie

Teliso-V is an investigational antibody–drug conjugate targeting c-Met, a receptor tyrosine kinase overexpressed in tumors, including Non-small Cell Lung Cancer. Teliso-V has the potential to become an important new treatment option in non-small cell lung cancer, with an anticipated approval in 2L+ NSCLC in 2024. In January 2022, AbbVie announced that the FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

• Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the most advanced programs in AstraZeneca’s ADC scientific platform and one of the three leading ADCs in the oncology pipeline of Daiichi Sankyo. In January 2023, a Phase III clinical trial, combined with immune checkpoint inhibitors for the first-line treatment for Non-Small Cell Lung Cancer without actionable genomic alterations, PD-L1 <50% (trial name: TROPION-Lung07), was initiated. No TROP2-directed therapies are currently approved for treating Non-Small Cell Lung Cancer patients. AstraZeneca and Daiichi Sankyo are interrogating Dato-DXd in 1L non-driver mutation patients with TROPION-Lung08 (trying to knock off the Keynote-024 regimen) and with TROPION-Lung07 (trying to dethrone Keynote-189 regimen, the most important indication for Merck’s KEYRTUDA), as well as covering 2L and 3L patients with TROPION-Lung01.

To learn more about Non-Small Cell Lung Cancer treatment guidelines, visit @ Non-Small Cell Lung Cancer Treatment Market Landscape

Non-Small Cell Lung Cancer Market Outlook

As more targetable mutations are discovered, and new targeted drugs are developed, patients and oncologists will have an expanding array of treatment options. Given the rapid pace of drug approvals, it is important to pause and ensure sufficient data supports the use of specific agents in the appropriate treatment settings, including adjuvant, consolidation, first-line, or subsequent therapy.

Non-Small Cell Lung Cancer Drugs Uptake

The existing NSCLC treatment is mainly dominated by targeted therapies for mutations such as EGFR-sensitizing mutations, EGFR exon 20 insertions, ALK fusions, ROS1 fusions, BRAFV600E mutation, MET exon 14 skipping mutations, RET fusions, and KRASG12C mutation. EGFR mutations and ALK rearrangements are well-known genetic abnormalities that drive the development of NSCLC. The use of TKIs as a treatment approach has shown better results in terms of patient outcomes when compared to chemotherapy. EGFR mutations are frequently observed, EGFR exon 19 deletions and EGFR exon 21 L858R mutations. The FDA has approved various TKIs to treat these mutations, with TAGRISSO considered the standard treatment. GILOTRIF is approved for patients with other EGFR sensitivity mutations like S768I, L861Q, and G719X.

Major Non-Small Cell Lung Cancer Companies

Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others.

Scope of the Non-Small Cell Lung Cancer Market Report

• Coverage- 7MM

• Study Period- 2020-2034

• Non-Small Cell Lung Cancer Companies- Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc., Sanofi, Agennix AG, and others., and others

• Non-Small Cell Lung Cancer Pipeline Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, Cisplatin, Gemcitabine, Furmonertinib 80 mg, ILX651 and others.

• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer Market Drivers and Barriers

• Non-Small Cell Lung Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content

1. Key Insights

2. Non-Small Cell Lung Cancer Executive Summary

3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis

4. Non-Small Cell Lung Cancer: Market Overview at a Glance

5. Non-Small Cell Lung Cancer: Disease Background and Overview

6. Patient Journey

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Small Cell Lung Cancer Unmet Needs

10. Key Endpoints of Non-Small Cell Lung Cancer Treatment

11. Non-Small Cell Lung Cancer Marketed Products

12. Non-Small Cell Lung Cancer Emerging Therapies

13. Non-Small Cell Lung Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Non-Small Cell Lung Cancer Market Outlook

16. Access and Reimbursement Overview of Non-Small Cell Lung Cancer

17. KOL Views

18. Non-Small Cell Lung Cancer Market Drivers

19. Non-Small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/